All News

Covid lung pneumonia corona (keep)

Baricitinib Therapy in Covid-19 Pneumonia

d Jack Cush, MD

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.

Read Article
obese.waist_.jpg

Weight Loss to Avert Risk of Gout

d Jack Cush, MD

Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.

Read Article
Telemedicine.MD.Computer.phone (keep)

Paucity of Effectiveness Research on Telemedicine in RA

d Jack Cush, MD

A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address comparable patient outcomes, implementation strategies and long‐term health system consequences. 

Read Article
Gout pills injection

Combo Therapy Boosts Response in Uncontrolled Gout

d MedPage Today

The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.

Read Article
IL-6 IL6 cells cytokine

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

d Jack Cush, MD

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

Read Article
Comparison of MSU crystal ID, DECT scanning and US to Dx gout - study of 147 pts. Compared to the gold standard (MSU ID), Feet/ankles (87% sensitivity; 100% specificity) or knees DECT (91% & 87%) alone had best Dx accuracy. US was inferior to DECT. https://t.co/h8ctkfeadZ

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Paucity of Effectiveness Research on Telemedicine in RA https://t.co/AoKnIZCYgA https://t.co/MCBfVoEvBX

Links:

Dr. John Cush RheumNow ( View Tweet)
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Links:

Dr. John Cush RheumNow ( View Tweet)

We are just weeks away from RheumNow Live--will you be attending? https://t.co/vJlU0Z3Q3x https://t.co/i1BhS4JQgi

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Don't Stop Believin' Rheumatic Patients Should NOT Stop DMARDs if the get COVID-19 https://t.co/0JAqwbatn0 https://t.co/3dzU1HHm5e

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Combo Therapy Boosts Response in Uncontrolled Gout https://t.co/K6tmYWqDCg https://t.co/Li9fcLnP4f

Links:

Dr. John Cush RheumNow ( View Tweet)
GSKs RCT showed otilimab (investigational anti-GM-CSF Ab) in severe COVID-19, was not superior to SOC for the primary endpoint - the proportion alive and free of respiratory failure at 28 days (but was effective in pts >70 yrs (65% vs 46%) https://t.co/OHvWGGlgKv

Links:

Dr. John Cush RheumNow ( View Tweet)

620 RA patients from Nordic biologics registers started a non-TNFi as 1steverr bDMARD but later switched to a 2nd bDMARD (ABA 86, RTX 40, TCZ 67 TNFi 427). Retention was 70% @ 6 mos & 50% @12 mos. 30-40% on 2nd bDMARD reached LDAS or remission https://t.co/u8BQn0rYca

Links:

Dr. John Cush RheumNow ( View Tweet)

Influenza vaccinations may hit a record high this season. Last year 48.4% of Americans got the flu shot. Survey suggests that nearly two-thirds will have flu vax this year (44% already had a flu shot, 13.5% said they will get& 9.3% said probably will get) https://t.co/3CnIdx49rW https://t.co/Khp6wsahCD

Links:

Dr. John Cush RheumNow ( View Tweet)
Report from DANBIO Danish register looked at chronic pain in a matched cohort study of Psoriasis. Chronic pain was not associated with excess mortality (hence not PsA) (OR 0.99,0.95-1.03). Mortality was increased with steriods, COPD, DM, CA, CV disease.  https://t.co/91JW3BOPtw

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19 https://t.co/IrKnTlPDpK https://t.co/8topsI3nQN

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Self-Medicating Myself Getting pills from Mexico, Spouse or the Dog? https://t.co/jcAmyhihN5 https://t.co/68UMEVCM6W

Links:

Dr. John Cush RheumNow ( View Tweet)
Top February Tweet: ACR Task Force published guidelines on RMD drug use w/ COVID vaccines. My views: 1. I agree, no change most DMARD, biologics 2. I disagree; I would NOT hold Orencia, I would NOT hold JAKi 3. I disagree: I would not hold MTX https://t.co/uSPfvJB8EC https://t.co/unOY1jvzTJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Compared with no statin use; statin use in RA pts is assoc w/ 28% lower mortality risk. Population study of 19,614 RA pts w/ incident statin use, compared 1,883 statin users vs 1,883 nonusers. All-cause mortality was lower (HR 0.72;0.56-0.91) w/ statins https://t.co/onMlWoVdPL

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Measureable Benefits to Treat-to-Target Management in RA https://t.co/iAvLWJGTXp https://t.co/NfNj3MWznI

Links:

Dr. John Cush RheumNow ( View Tweet)
×